Skip to content

A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China

A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03173352
Acronym
IH
Enrollment
10000
Registered
2017-06-01
Start date
2015-12-31
Completion date
2017-09-30
Last updated
2017-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capillary Hemangioma, Capillary Hemangiomas, Hemangioma, Capillary Infantile, Infantile Hemangioma, Strawberry Hemangioma

Keywords

Hemangioma

Brief summary

Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, the investigators designed the study for the following purposes: 1, to aware the incidence of infantile hemangioma and understand the related risk factorsin China; 2, to understand the clinical characteristics of infantile hemangioma and the risk factors for complications; 3, to investigate the level of knowledge, treatment options in infant hemangioma in Chinese doctors; 3, to improve the awareness of infantile hemangioma in parents and provide more advice for pregnancy counseling and eugenics.

Interventions

None listed

Sponsors

Zhujiang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 12 Months
Healthy volunteers
Yes

Inclusion criteria

* Chinese * The infants within 12 months of age

Exclusion criteria

* Those whoes guardian does not want his data to be collected in this study

Design outcomes

Primary

MeasureTime frameDescription
The incidence rate of infantile hemangioma in Chinaabout 1 yearsData collected by questionnaire of infantile hemangioma, filled by the investigators

Countries

China

Contacts

Primary ContactXiaojian XJ Yao, MBBS
yaoxiaojian321@163.com+8613631344241

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026